Press release 2012-08-29
US patent granted for the C-RAD Catalyst™ system
C-RAD AB with its three fully owned subsidiaries in Sweden and three international sales companies are all active in the field of radiation therapy. The US Patent and Trademark Office has recently issued a comprehensive patent which protects the unique features of the Catalyst™ system on the US market.
The Catalyst™ is a next-generation high performance tracking system based on optical surface scanning and augmented reality through re-projection. Advanced and highly optimized algorithms for non-rigid registration and deformable models enable clinicians to perform a real-time assessment of patient positioning errors before and during treatment delivery. Interfaces to major vendors ensure a completely integrated workflow.
The recently issued US patent will ensure that C-RAD maintains the exclusive right to market and sell solutions based on the advanced principles underlying the Catalyst™ system. The US radiation therapy market represents 50% of the total world market. At the same time, the US patent system is widely regarded as offering the best protection worldwide for new innovations.
Erik Hedlund, CEO, C-RAD AB:
”The new US patent again proves the innovative strength of the C-RAD group. In light of the remarkable interest received for the Catalyst™ system from end users as well as industrial partners, the patent forms a strong asset and will enable new sales as well as licensing opportunities.”
For further information:
Erik Hedlund, CEO C-RAD AB, Phone +46-(0)18-66 69 31, E-Mail erik.hedlund@c-rad.com
